SHINGRIX POWDER AND SUSPENSION FOR SUSPENSION FOR INJECTION 50MCG/0.5ML

GLAXOSMITHKLINE PTE LTD

GLAXOSMITHKLINE PTE LTD

Therapeutic

Prescription Only

INJECTION, POWDER, LYOPHILIZED, FOR LIPOSOMAL SUSPENSION

**Dosage and Administration** The immunisation schedule for _Shingrix_ should be based on official recommendations. **Posology** The primary vaccination schedule consists of two doses of 0.5 ml each; an initial dose followed by a second dose 2 to 6 months later. For subjects who are immunodeficient, immunosuppressed or likely to become immunosuppressed due to known disease or therapy, and whom would benefit from a shorter vaccination schedule, the second dose can be given 1 to 2 months after the initial dose (see _Pharmacodynamic Effects_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). The need for booster doses has not been established. _Shingrix_ can be given with the same schedule in individuals previously vaccinated with live attenuated HZ vaccine (see _Pharmacodynamic Effects_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_). _Shingrix_ is not indicated for prevention of primary varicella infection. **Method of administration** _Shingrix_ is for intramuscular injection only, preferably in the deltoid muscle. For instructions on reconstitution of the medicinal product before administration, see _Instructions for Use/Handling_ – _please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information_.